Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer...
October 04 2016 - 8:00AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on cancer, today announced the appointment of Sergey
Yurasov, M.D., Ph.D. as Senior Vice President of Clinical
Development and Chief Medical Officer.
“Sergey’s extensive experience and successful
track record in immunology and in the various stages of clinical
oncology drug development, including registration trials and
regulatory submissions and reviews, make him the optimal leader of
our medical team,” said Carlos Paya, M.D., Ph.D., President and
Chief Executive Officer at Immune Design. “His esteemed career as
an immunologist and oncologist spans industry, academia and
clinical practice and will bring invaluable expertise and insight
to guide the further advancement of our current Phase 2 stage
products and our next-generation approaches in the field of cancer
immunotherapy.”
A board-certified, U.S. licensed
hematologist/oncologist with more than 20 years of experience in
immunology and oncology, Dr. Yurasov joins Immune Design from
Clovis Oncology, where he most recently served as Senior Vice
President, Clinical Development overseeing all clinical activities
for its rociletinib, rucaparib and lucitanib programs, including
regulatory approval and launch support for rociletinib and
rucaparib. Prior to Clovis, Dr. Yurasov served as Associate
Vice-President, Global Medicine Science, at ImClone Systems, a
subsidiary of Eli Lilly & Co. where he led the development of
ramucirumab culminating in the FDA submission for second line
non-small cell lung cancer indication. He also served at Hoffman-La
Roche as Clinical Director of Oncology, Pharma Research and Early
Development. Prior to his industry experience, Dr. Yurasov was
Assistant Professor of Clinical Investigation at Rockefeller
University, where he was the principal investigator for NIH funded
translational immunology research, and Clinical Instructor in the
Department of Pediatrics at Memorial Sloan-Kettering Cancer Center,
where he was an attending physician.
Dr. Yurasov received his M.D. from the Russian
State Medical University and his Ph.D. in medical sciences from the
Research Institute for Pediatric Oncology in Moscow, Russia.
He thereafter completed his residency in general pediatrics at
Albert Einstein College of Medicine/Jacobi Medical Center and his
subspecialty training in pediatric hematology/oncology at Memorial
Sloan-Kettering Cancer Center while serving as a research fellow at
The Rockefeller University in Dr. M. Nussenzweig’s laboratory.
"Immune Design’s immunotherapy approaches offer
a promising approach to address the shortcomings of existing
therapies, either alone or in combination with other agents," said
Dr. Yurasov. "It is rewarding to be involved in such innovative
science at the forefront of cancer research. I am pleased to join
this distinguished team and look forward to help guide the
development of these innovative product candidates."
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the two-pronged focus of
Immune Design's ongoing immuno-oncology clinical programs, are the
product of its two synergistic discovery platforms,
ZVex® and GLAASTM. Immune Design has offices in
Seattle and South San Francisco. For more information, visit
www.immunedesign.com.
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024